Syros Pharmaceuticals, Inc.
SYRSOTCHealthcare● Active
$0.00
$-0.00(-50.00%)
Market Cap$5366
P/E Ratio—
52W High$0.04
52W Low$0.0001
Syros Pharmaceuticals, Inc. (SYRS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SYRS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $9.94M | $14.88M | $23.49M | $15.09M | $1.98M |
| Cost of Revenue | $2.25M | $2.97M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $7.68M | $11.91M | $23.49M | $15.09M | $1.98M |
| Gross Margin %(computed) | 77.33% | 80.06% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $108.15M | $111.94M | $99.87M | $76.06M | $58.24M |
| G&A Expenses | $28.28M | $29.30M | $23.04M | $21.32M | $21.48M |
| Total Operating Expenses | $30.77M | $38.81M | $122.91M | $97.39M | $79.72M |
| Operating Income | ($128.99M) | ($135.87M) | ($99.42M) | ($82.30M) | ($77.74M) |
| Operating Margin %(computed) | — | -913.13% | -423.28% | -545.27% | — |
| Interest Income | $6.82M | $2.13M | $0.09M | $0.43M | $2.30M |
| Interest Expense | $5.13M | $4.13M | $3.91M | $1.79M | $0.00M |
| Income Before Tax | ($164.57M) | ($94.65M) | ($86.56M) | ($84.04M) | ($75.44M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($164.57M) | ($94.65M) | ($86.56M) | ($84.04M) | ($75.44M) |
| Net Margin %(computed) | — | -636.12% | -368.52% | -556.80% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.81 | $-7.49 | $-13.84 | $-18.25 | $-18.76 |
| Wtd Avg Shares | 28.33M | 12.63M | 6.25M | 4.61M | 4.02M |
| EBITDA | ($157.19M) | ($87.55M) | ($79.63M) | ($79.21M) | ($72.72M) |
| EBITDA Margin %(computed) | — | -588.39% | -339.04% | -524.82% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Syros Pharmaceuticals, Inc. data
About Syros Pharmaceuticals, Inc. (SYRS) Income Statement
Syros Pharmaceuticals, Inc. (SYRS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, SYRS reported revenue of $0.01B, gross profit of $0.01B (gross margin 77.33%), and net income of ($0.16B) — a net profit margin of -1656.34%.
Frequently asked questions
SYRS · 4 questionsSyros Pharmaceuticals, Inc. (SYRS) reported revenue of $0.01B for 2023, down 33.2% year-over-year.
SYRS revenueSYRS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09